XAGE-1 Inhibitors
The term XAGE-1 inhibitors refers to a class of chemical compounds designed to target and modulate the activity of the XAGE-1 gene or its protein product. XAGE-1, which stands for X Antigen Family Member 1, is a relatively newly discovered gene that has garnered attention primarily for its association with various cancers, particularly in the context of cancer immunotherapy and diagnostics. These inhibitors are specifically engineered to interfere with the expression or function of XAGE-1, typically at the molecular level.
At the molecular level, XAGE-1 inhibitors can encompass a diverse range of compounds, including small molecules or peptides, which may exert their inhibitory effects through various mechanisms. Some inhibitors may function by directly binding to XAGE-1 mRNA or the protein product, thereby blocking its translation or promoting its degradation. Others may target signaling pathways or transcription factors involved in the regulation of XAGE-1, indirectly downregulating its expression. The overarching goal of this chemical class is to reduce or eliminate the activity of XAGE-1 in the context of cancer research, with the aim of elucidating its precise role in tumorigenesis and exploring diagnostic and applications. While the implications of XAGE-1 inhibitors remain an active area of research, their development represents a critical step in unraveling the intricacies of XAGE-1 biology and its significance in cancer development and progression, paving the way for future applications in cancer management.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is a small molecule tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR). It inhibits the autophosphorylation of EGFR and downstream signaling pathways, blocking cell proliferation and promoting apoptosis in cancer cells. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib inhibits multiple kinases, including Raf kinase and vascular endothelial growth factor receptor (VEGFR), disrupting cell signaling in cancer cells and blocking tumor angiogenesis. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is an EGFR tyrosine kinase inhibitor that competes with ATP for binding to EGFR, blocking downstream signaling pathways and inhibiting cancer cell growth. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib targets BCR-ABL tyrosine kinase, disrupting the signaling pathways responsible for chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib inhibits both EGFR and HER2 kinases, interfering with their autophosphorylation and downstream signaling, leading to cell cycle arrest and apoptosis in breast cancer cells. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib targets multiple tyrosine kinases, including BCR-ABL and Src family kinases. It inhibits these kinases' activities, blocking cancer cell growth and metastasis in various malignancies. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib targets multiple receptor tyrosine kinases, including VEGFR and PDGFR. It inhibits angiogenesis and tumor cell proliferation, making it effective against various cancers. | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Vandetanib is a multi-kinase inhibitor that targets EGFR, VEGFR, and RET. It hinders angiogenesis, disrupts cell signaling, and induces apoptosis, primarily in medullary thyroid cancer (MTC) cells. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
Nilotinib is a BCR-ABL tyrosine kinase inhibitor with a mechanism similar to Imatinib. | ||||||
CH5424802 | 1256580-46-7 | sc-364461 sc-364461A | 5 mg 50 mg | $191.00 $902.00 | ||
Alectinib is a selective ALK inhibitor that binds to ALK and inhibits its activity, blocking the ALK signaling pathway in NSCLC cells with ALK gene rearrangements, leading to tumor regression. | ||||||